# A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line

Source: https://onco.cc/trials/nct07502014/  
OnCo record `nct07502014` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of iparomlimab and tuvonralimab and fruquintinib in colorectal cancer, run by Huazhong University of Science and Technology, not yet recruiting.

## Summary

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07502014 by Huazhong University of Science and Technology, with a registry enrolment figure of 60 participants, started 2026-05-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Iparomlimab and Tuvonralimab (QL1706); Fruquintinib; Heterogeneous Radiotherapy. Conditions listed: Metastatic Colorectal Cancer (CRC); mCRC. Primary outcome: Progression-Free Survival. Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed stage Ⅳ primary colorectal cancer". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07502014
- Phase: 2
- Setting: A Randomized, Parallel, Open-Label, Multicenter Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
- Sponsor: Huazhong University of Science and Technology
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07502014: https://clinicaltrials.gov/study/NCT07502014

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07502014.json